Skip to main content
Premium Trial:

Request an Annual Quote

Admera Health PGxOnco and LiquidGx Tests

Admera Health has launched two new tests: PGxOnco for cancer supportive care, and LiquidGx, a suite of liquid biopsy-based tests for tumor profiling and drug resistance monitoring. The PGxOnco test includes 50 genes and about 200 variants, and provides recommendations for over 300 drugs via next-generation sequencing. LiquidGx represents a menu of both qPCR and a NGS tests that analyze tumor DNA in blood samples. PCR assays allows for the genotyping of ALK, BRAF, EGFR, and KRAS either individually or together. The NGS panel, aimed specifically at lung cancer, includes AKT1, BRAF, ERBB2, MET, RET, ALK, EGFR, KRAS, PIK3CA,and ROS1.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more